Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The partnership initially will focus on cardiovascular and kidney diseases
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
Subscribe To Our Newsletter & Stay Updated